That’s all true, but it also assumes a successful outcome. It’s possible that Anavex would have been unlucky with its patient cohort or there’s a pandemic or whatever that results in failure, even with a large and expensive trial and then Anavex is trading around $0,40/share. Hindsight is 20:20.
I’d take a few additional years of waiting and accumulating shares, gathering data to inform future trials, then blowing it all on one turn of pitch and toss. As is there’s no guarantee for Blarcamesine with the EMA so I’m grateful we have 4 years of runway just in case we need to turn attention to 371.
Spending more may have produced better results but it’s way to be aggressive with other people’s money. If Dr M spent hundreds of millions and the trial still failed, people wouldn’t be happy either. The hope was low spend with a passing trial but that didn’t happen. Rett was just a placeholder while the mAb drugs proved to the world they’re not the answer,